Trials / Completed
CompletedNCT03363321
PF-06741086 Long-term Treatment in Severe Hemophilia
A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 12 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PF-06741086 | PF-06741086 subcutaneous injection |
Timeline
- Start date
- 2018-05-30
- Primary completion
- 2020-08-05
- Completion
- 2020-08-05
- First posted
- 2017-12-06
- Last updated
- 2021-07-27
- Results posted
- 2021-07-27
Locations
8 sites across 7 countries: United States, Brazil, Chile, Croatia, Poland, South Africa, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03363321. Inclusion in this directory is not an endorsement.